Drug Prices
The Health, Education, Labor and Pensions Committee today held the first in a series of hearings on how to reduce health care costs, which will examine administrative costs and waste, how to improve transparency, private sector solutions and other issues.
The Senate Finance Committee today held a hearing on strategies to reduce prescription drug costs and encourage innovation and competition in the market.
AHA statement before the Senate Finance Committee on Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market.
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding “Effective Administration of the 340B Drug Pricing Program.”
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, and our clinician partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership…
The Senate Health, Education, Labor & Pensions Committee today held a hearing examining the administration’s blueprint to lower prescription drug prices.
The American Hospital Association and others support Senators Grassley and Feinstein of the Senate Judiciary Committee for their leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high.
Read the full letter below…
Total reimbursement for brand-name prescription drugs in Medicare Part D increased 77% between 2011 and 2015, nearly six times faster than inflation, despite a 17% decrease in the number of prescriptions.
The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
AHA today urged the Health Resources and Services Administration to implement without further delay its final regulation on 340B drug ceiling prices and civil monetary penalties for manufacturers.